Ventyx Biosciences (VTYX) Stock Overview
A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VTYX Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ventyx Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.42 |
| 52 Week High | US$8.52 |
| 52 Week Low | US$0.78 |
| Beta | 1.01 |
| 1 Month Change | 170.74% |
| 3 Month Change | 220.15% |
| 1 Year Change | 289.81% |
| 3 Year Change | -74.26% |
| 5 Year Change | n/a |
| Change since IPO | -59.94% |
Recent News & Updates
Ventyx Biosciences: At Last, A Data Win In CV - But Clarity On Next Steps Needed
Oct 23Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?
Sep 23
Recent updates
Ventyx Biosciences: At Last, A Data Win In CV - But Clarity On Next Steps Needed
Oct 23Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?
Sep 23Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?
May 05We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully
Nov 14Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Nov 04Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
Jul 12Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
Jul 01Ventyx Pivots To Obesity Amid Transformation
Mar 12Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation
Feb 15Ventyx: Too Risky Right Now After Some Poor Data
Jan 18Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth
Sep 21Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Feb 20Ventyx Biosciences: Not Chasing This Rally
Sep 18We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Aug 19Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06
Aug 15Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals
Jun 29Shareholder Returns
| VTYX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 27.6% | 0.8% | 0.5% |
| 1Y | 289.8% | 0.4% | 19.8% |
Return vs Industry: VTYX exceeded the US Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: VTYX exceeded the US Market which returned 19% over the past year.
Price Volatility
| VTYX volatility | |
|---|---|
| VTYX Average Weekly Movement | 24.2% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VTYX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VTYX's weekly volatility has increased from 17% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 81 | Raju Mohan | ventyxbio.com |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn’s disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.
Ventyx Biosciences, Inc. Fundamentals Summary
| VTYX fundamental statistics | |
|---|---|
| Market cap | US$525.54m |
| Earnings (TTM) | -US$119.03m |
| Revenue (TTM) | n/a |
Is VTYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTYX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$119.03m |
| Earnings | -US$119.03m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VTYX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 11:19 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ventyx Biosciences, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Nash | Canaccord Genuity |
| Chris Shibutani | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |